Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
about
Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonistsBuprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivativesHydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.Novel 6β-acylaminomorphinans with analgesic activity.Role of µ-opioid receptor reserve and µ-agonist efficacy as determinants of the effects of µ-agonists on intracranial self-stimulation in ratsStructural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinonesCinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro AssaysSynthesis and pharmacological evaluation of novel selective MOR agonist 6β-pyridinyl amidomorphines exhibiting long-lasting antinociception.
P2860
Q28343629-C5C3E493-4F21-4FC0-B906-ED792A6494B4Q33837577-A090C87A-6F10-4D25-B737-1FEED7FA441AQ33902436-156B8E85-8578-4767-A584-FB19382609C7Q36016398-F171E5E2-3624-45CE-B720-6E12770AFEF0Q36107406-AB24A809-54FA-4530-B766-C7E9D3494692Q36982400-0BEB27B8-7091-4EA0-9A62-D80D84C4FDF6Q37340566-5DB3A3EC-2034-43C2-9306-408285349D09Q37394355-54A51CC3-BCD7-4593-BEE9-3C969C928CC0Q39671329-194FF075-2E0C-4444-9BE0-FC3440A6EDDBQ41134315-307EDA9B-B09D-4A57-8C3E-34E3B51BF2F0Q42699426-B18C1FAA-5E04-4A62-9D2B-A2F11E23C652Q42713279-827AED80-3960-4029-9EA0-F8E7A8A3CC6CQ47147106-AE86BECE-E78A-4341-8B28-A09C550ADA8A
P2860
Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
@en
Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
@nl
type
label
Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
@en
Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
@nl
prefLabel
Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
@en
Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
@nl
P2093
P1476
Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
@en
P2093
P304
P407
P577
1992-09-01T00:00:00Z